文献速递慢性肾脏病

非奈利酮与合并2型糖尿病的慢性肾脏病患者按衰弱指数分层的临床结局:FIDELITY事后分析

Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-05-02

该研究为FIDELIO-DKD与FIGARO-DKD预设汇总分析的事后分析,纳入12,990例合并2型糖尿病且已接受最大耐受剂量肾素-血管紧张素系统抑制剂的慢性肾脏病患者,按基线衰弱指数评估非奈利酮与安慰剂的疗效与安全性。结果显示,无论基线衰弱程度如何,非奈利酮均降低肾脏与心血管复合结局风险,且各衰弱亚组中不良事件相对风险在治疗组间保持一致。

要点

  • 在合并2型糖尿病的慢性肾脏病患者中,衰弱与不良结局风险升高相关。
  • 无论基线衰弱程度如何,非奈利酮均降低肾脏与心血管复合结局风险。
  • 非奈利酮耐受性良好,各衰弱亚组中治疗组间不良事件相对风险保持一致。

核心结论

  • 与安慰剂相比,非奈利酮降低合并2型糖尿病的慢性肾脏病患者的肾脏与心血管事件风险,且不受基线衰弱状态影响。

研究设计与样本

  • FIDELIO-DKD与FIGARO-DKD 3期临床试验的预设汇总分析(FIDELITY)的事后分析。
  • 2015年9月至2018年10月期间,12,990例合并2型糖尿病且接受最大耐受剂量肾素-血管紧张素系统抑制剂的慢性肾脏病患者随机接受非奈利酮10或20 mg每日一次或安慰剂。
  • 基线衰弱指数采用Rockwood累积缺陷法计算,纳入30项临床特征。

主要发现

  • 总体上,肾脏与心血管事件发生率随衰弱程度增加而升高。
  • 非奈利酮降低主要肾脏与心血管复合结局风险,且不受基线衰弱影响(交互作用P值分别为0.93与0.35)。
  • 与安慰剂相比,非奈利酮在所有衰弱亚组中均显著降低尿白蛋白与肌酐比值(所有访视P < 0.01)。
  • 与安慰剂相比,非奈利酮在三个最衰弱四分位组中显著减缓从基线至第48个月的eGFR下降(>Q1至≤Q2,P = 0.001;>Q2至≤Q3,P < 0.001;>Q3,P < 0.001)。
  • 两个治疗组中,严重不良事件与高钾血症发生率均随衰弱程度增加而升高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Frailty is associated with a higher risk of adverse outcomes in people with CKD and type 2 diabetes. Finerenone reduced the risk of kidney and cardiovascular outcomes irrespective of baseline frailty. Finerenone was well tolerated; the relative risk of adverse events remained consistent between treatment arms across the frailty subgroups. BACKGROUND: Frailty is associated with a higher risk of adverse outcomes. It is believed that people with a higher frailty index (FI) may be less tolerant to new treatments, often leading to inappropriate prescribing. This post hoc analysis of FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FInerenone in reducing kiDnEy faiLure and dIsease prOgression in Diabetic Kidney Disease (FIDELIO-DKD) and FIGARO-DKD Trial program analysis, a prespecified, pooled analysis of the FIDELIO-DKD and FIGARO-DKD phase 3 clinical trials, investigated the efficacy and safety of finerenone versus placebo according to baseline FI. METHODS: Between September 2015 and October 2018, 12,990 people with CKD and type 2 diabetes receiving the maximum tolerated dose of a renin-angiotensin system inhibitor were randomized to receive finerenone 10 or 20 mg once daily or placebo. Baseline FI was calculated using the Rockwood cumulative deficit approach including 30 clinical characteristics. Primary efficacy outcomes included a kidney (kidney failure, sustained decrease of ≥57% in eGFR, or kidney-related death) and a cardiovascular (CV) composite outcome (CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure). Changes in urine albumin-to-creatinine ratio and eGFR were measured across the study period. RESULTS: Overall, kidney and CV event rates increased with increasing frailty. Finerenone reduced the risk of primary kidney and CV composite outcomes irrespective of baseline frailty (P interaction = 0.93 and 0.35, respectively). Compared with placebo, finerenone also demonstrated significant reductions in urine albumin-to-creatinine ratio across all frailty subgroups (P < 0.01 for all visits) and significant attenuation of eGFR decline from baseline to month 48 in the three most frail quartiles (>Q1 to ≤Q2, P = 0.001; >Q2 to ≤Q3, P < 0.001; >Q3, P < 0.001, respectively). The incidence of serious adverse events and hyperkalemia increased with increasing frailty in both treatment arms. CONCLUSIONS: Finerenone reduced the risk of CV and kidney events in people with CKD and type 2 diabetes versus placebo irrespective of baseline frailty status. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: FIDELIO-DKD (NCT02540993) and FIGARO-DKD (NCT02545049).

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rossing P, Birkenfeld AL, Fioretto P, et al. Finerenone and Clinical Outcomes in CKD and Type 2 Diabetes by Frailty Index: FIDELITY Post Hoc Analysis. Clin J Am Soc Nephrol. 2025. PMID: 40315020. doi:10.2215/CJN.0000000700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。